We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Lilly's (LLY) Jardiance Gets Breakthrough Therapy Tag for HFpEF
Read MoreHide Full Article
Eli Lilly and Company (LLY - Free Report) along with partner Boehringer Ingelheim announced that the FDA has granted a Breakthrough Therapy designation to their SGLT-2 inhibitor Jardiance (empagliflozin) for the treatment of adult patients with heart failure with preserved ejection fraction (HFpEF).
A Breakthrough Therapy status is granted to medicines being evaluated for serious conditions where early clinical evidence indicates the said medicines’ potential for substantial improvement over available therapies.
The Breakthrough Therapy tag was based on data from the EMPEROR-Preserved phase III study, which evaluated Jardiance in adults with HFpEF.
In July 2021, Lilly announced that its EMPEROR-Preserved phase III study met the primary endpoint.
Top-line data from the study showed that Jardiance significantly reduced the risk of the composite of cardiovascular death or hospitalization for heart failure versus placebo in patients with HFpEF, with and without diabetes.
Per management, this is the first time that any medicine-improved outcome in a study for HFpEF, which is the most challenging form of heart failure to treat. Regulatory submissions for the HFpEF indication are expected to be filed later this year.
Shares of Lilly have rallied 42.1% so far this year compared with the industry’s increase of 13.2%.
Image Source: Zacks Investment Research
Last month, the FDA granted an approval to Jardiance for reducing the risk of cardiovascular death plus hospitalization for another form of heart failure in adults, which is a heart failure with reduced ejection fraction (HFrEF) regardless of whether they have type II diabetes.
The supplemental new drug application (sNDA) for the HFrEF indication was based on data from the phase III EMPEROR-Reduced study.
If approved for both HFrEF and HFpEF indications in the United States, Jardiance will become the first SGLT2 inhibitor to treat the full spectrum of heart failure patients regardless of ejection fraction.
We note that Jardiance is a key top-line driver for Lilly. In the first six months of 2021, it generated sales worth $668.5 million, up 26.2% year over year. The approval for the HFrEF indication and a potential nod to the HFpEF indication can boost sales higher in the future quarters.
Jardiance is also approved to reduce cardiovascular death in adults with type II diabetes and cardiovascular disease. A phase III study on Jardiance for chronic kidney disease is ongoing.
Other SGLT2 inhibitors available in the market are J&J’s (JNJ - Free Report) Invokana and AstraZeneca’s (AZN - Free Report) Farxiga/Forxiga.
Regeneron’s earnings estimates have been revised 9.3% upward for 2021 and 6.7% for 2022 over the past 60 days. The stock has surged 33.8% year to date.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Shutterstock
Lilly's (LLY) Jardiance Gets Breakthrough Therapy Tag for HFpEF
Eli Lilly and Company (LLY - Free Report) along with partner Boehringer Ingelheim announced that the FDA has granted a Breakthrough Therapy designation to their SGLT-2 inhibitor Jardiance (empagliflozin) for the treatment of adult patients with heart failure with preserved ejection fraction (HFpEF).
A Breakthrough Therapy status is granted to medicines being evaluated for serious conditions where early clinical evidence indicates the said medicines’ potential for substantial improvement over available therapies.
The Breakthrough Therapy tag was based on data from the EMPEROR-Preserved phase III study, which evaluated Jardiance in adults with HFpEF.
In July 2021, Lilly announced that its EMPEROR-Preserved phase III study met the primary endpoint.
Top-line data from the study showed that Jardiance significantly reduced the risk of the composite of cardiovascular death or hospitalization for heart failure versus placebo in patients with HFpEF, with and without diabetes.
Per management, this is the first time that any medicine-improved outcome in a study for HFpEF, which is the most challenging form of heart failure to treat. Regulatory submissions for the HFpEF indication are expected to be filed later this year.
Shares of Lilly have rallied 42.1% so far this year compared with the industry’s increase of 13.2%.
Image Source: Zacks Investment Research
Last month, the FDA granted an approval to Jardiance for reducing the risk of cardiovascular death plus hospitalization for another form of heart failure in adults, which is a heart failure with reduced ejection fraction (HFrEF) regardless of whether they have type II diabetes.
The supplemental new drug application (sNDA) for the HFrEF indication was based on data from the phase III EMPEROR-Reduced study.
If approved for both HFrEF and HFpEF indications in the United States, Jardiance will become the first SGLT2 inhibitor to treat the full spectrum of heart failure patients regardless of ejection fraction.
We note that Jardiance is a key top-line driver for Lilly. In the first six months of 2021, it generated sales worth $668.5 million, up 26.2% year over year. The approval for the HFrEF indication and a potential nod to the HFpEF indication can boost sales higher in the future quarters.
Jardiance is also approved to reduce cardiovascular death in adults with type II diabetes and cardiovascular disease. A phase III study on Jardiance for chronic kidney disease is ongoing.
Other SGLT2 inhibitors available in the market are J&J’s (JNJ - Free Report) Invokana and AstraZeneca’s (AZN - Free Report) Farxiga/Forxiga.
Zacks Rank & Key Pick
Lilly currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Regeneron Pharmaceuticals, Inc. (REGN - Free Report) , which sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Regeneron’s earnings estimates have been revised 9.3% upward for 2021 and 6.7% for 2022 over the past 60 days. The stock has surged 33.8% year to date.